natgillin/translations-raw huggingface dataset:
5 ampoules, each containing 2,000 or 4,000 doses of cell suspension (attached to the cane is a coloured clip displaying the dose; 2,000 doses: salmon-pink coloured clip, and 4,000 doses: yellow coloured clip). 
Velikosti pakiranj - 5 ampul, vsaka vsebuje 2.000 or 4.000 odmerkov suspenzije celic, na nizu je barvna priponka, ki kaže odmerek (2.000 odmerkov: lososovo rožnata priponka, 4.000 odmerkov:
Special warnings for each target species: Vaccinate healthy one-day-old chicks only. 
4.4 Posebna opozorila za vsako ciljno živalsko vrsto Cepite samo zdrave enodnevne piščance.
Container: Store liquid nitrogen container securely in upright position in a clean, dry and well-ventilated room separated from the hatching/chicken room in the hatchery. 
Posoda: Posodo s tekočim dušikom shranjujte varno v pokončnem položaju v čistem, suhem in dobro prezračevanem prostoru, ločeno od prostora, kjer se valijo piščanci v valilnici.
Use solvent (Solvent for cell associated poultry vaccines) for reconstitution. 
Za rekonstitucijo uporabite vehikel (Vehikel za cepiva za perutnino, vezana na celice).
Remove the washing from the ampoule and inject it gently into the solvent bag. 
Odstranite spiralno tekočino iz ampule in jo pazljivo injicirajte v vrečko z vehiklom.
ROUTE(S) OF ADMINISTRATION Read package leaflet before use. 
Pred uporabo preberite navodilo za uporabo.
The bag of vaccine should be gently swirled frequently during vaccination to guarantee that the vaccine suspension remains homogenous and that the correct vaccine virus titre is administered (e.g. during long vaccination sessions). 
da je zagotovljeno, da suspenzija za injiciranje ostane homogena in da je dan pravilni titer vakcinalnega virusa (npr. med dolgimi postopki cepljenja)
The solvent must be clear, red coloured, without sediment and at room temperature (15-25 °C) at the time of mixing. 
V času mešanja mora biti vehikel bister, rdeče obarvan, brez sedimenta in pri sobni temperaturi (15-25 °C).
For active immunization of one-day-old chicks to reduce mortality, clinical signs and lesions due to infection with avian infectious laryngotracheitis (ILT) virus and Marek's disease (MD) virus. 
INDIKACIJE Za aktivno imunizacijo enodnevnih piščancev za zmanjšanje smrtnosti, kliničnih znakov in poškodb zaradi infekcije z virusom aviarnega infekcijskega laringotraheitisa (ILT) in virusa Marekove bolezni (MB).
After removing the ampoule(s), the remaining ampoules should be put back immediately into the canister in the liquid nitrogen container. 
Ko vzamete ampule ven, je treba preostale takoj dati nazaj v kanister v posodi s tekočim dušikom.
The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009. 
C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL) Učinkovina biološkega izvora, namenjena vzbujanju aktivne imunosti, ni vključena v Uredbo (ES) št.
Posology: One single injection of 0.2 ml per chick at the age of one day, by the subcutaneous route. 
Ena injekcija 0,2 ml na enodnevnega piščanca, subkutano
Store liquid nitrogen container securely in upright position in a clean, dry and well-ventilated room separated from the hatching/chicken room in the hatchery. 
Posodo s tekočim dušikom shranjujte varno v pokončnem položaju v čistem, suhem in dobro prezračevanem prostoru, ločeno od prostora, kjer se valijo piščanci v valilnici.
Shelf life of the solvent (multilayer plastic bags) as packaged for sale: 2 years. 
Rok uporabnosti vehikla (polietilenske vrečke) v pakiranju za prodajo: 3 leta Rok uporabnosti vehikla (večslojne plastične vrečke) v pakiranju za prodajo: 2 leti
Name and address of the manufacturer of the biological active substance 
Ime in naslov izdelovalca biološke zdravilne učinkovine Intervet Inc.
29160 Intervet Lane PO Box 318, Millsboro Delaware 19966-0318 
PO Box 318, Millsboro
NAME OF THE VETERINARY MEDICINAL PRODUCT Innovax-ILT, suspension and solvent for suspension for injection for chickens 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI Innovax-ILT, suspenzija in vehikel za suspenzijo za injiciranje za piščance
STORAGE CONDITIONS Store below 25 °C. 
Shranjujte pri temperaturi pod 25 °C.
Chickens. 
Piščanci
PACKAGE LEAFLET: Innovax-ILT suspension and solvent for suspension for injection for chickens 
NAVODILO ZA UPORABO Innovax-ILT suspenzija in topilo za suspenzijo za injiciranje za piščance
Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus: 
Na celico vezan živ rekombinantni puranji herpes virus (sev HVT/ILT- 138) z izraženima glikoproteinoma gD in gI virusa kužnega laringotraheitisa:
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION After dilution, administer 1 dose of 0.2 ml of vaccine per chicken by subcutaneous injection in the neck. 
Po razredčenju dajte en odmerek 0,2 ml cepiva na piščanca subkutano v vrat.
The vaccine is a cell-associated live recombinant turkey herpesvirus (HVT) expressing the gD and gI glycoproteins of infectious laryngotracheitis virus. 
Cepivo je na celico vezan živ rekombinantni puranji virus herpesa (HVT), ki izraža gD in gI glikoproteine kužnega virusa laringotraheitisa.
5 bags of 400 ml solvent or 5 bags of 800 ml solvent. 
5 vrečk po 400 ml vehikla ali 5 vrečk po 800 ml vehikla Ni nujno, da so v prometu vsa navedena pakiranja.
PHARMACEUTICAL FORM Suspension and solvent for suspension for injection. 
Suspenzija in vehikel za suspenzijo za injiciranje
TARGET SPECIES 
CILJNE ŽIVALSKE VRSTE Piščanci
Before withdrawing ampoules from the liquid nitrogen canister, protective equipment consisting of gloves, long sleeves and a facemask and goggles should be worn. 
Preden vzamete ampule iz posode s tekočim dušikom, si je treba nadeti zaščitno opremo, tj. rokavice, dolge rokave, obrazno masko in zaščitna očala.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: The handling of liquid nitrogen should take place in a well-ventilated area. 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo za uporabo v veterinarski medicini Innovax-ILT je virusna suspenzija, pakirana v steklenih ampulah in hranjena v tekočem dušiku.
MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE IN IMETNIK DOVOLJENJ(A) ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
NAME OF THE VETERINARY MEDICINAL PRODUCT Innovax-ILT 
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE SOLVENT BAG 
PODATKI, KI MORAJO BITI NAVEDENI NA STIČNI OVOJNINi
ANNEX II A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND> MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
IZDELOVALEC(IZDELOVALCI) BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN>IMETNIK(I) DOVOLJENJ(A) ZA IZDELAVO ZDRAVILA, ODGOVOREN(ODGOVORNI) ZA SPROŠČANJE SERIJE
NAME OF THE VETERINARY MEDICINAL PRODUCT Solvent for cell associated poultry vaccines 
Vehikel za cepiva za perutnino, vezana na celice.
Veterinary medicinal product subject to prescription. 
Na veterinarski recept
Duration of immunity: ILT: 60 weeks, MD: entire risk period. 
Mb: celotno obdobje tveganja
Suspension: - Type I glass ampoules containing 2,000 or 4,000 doses. 
Suspenzija: - Steklene ampule, steklo tipa I, z 2.000 ali 4.000 odmerki, 5 ampul na niz, na nizu je barvna priponka, ki kaže odmerek (2.000 odmerkov: lososovo rožnata priponka, 4.000 odmerkov:
Cell suspension: Store and transport frozen in liquid nitrogen (-196 °C). 
Suspenzija celic: Shranjujte in prevažajte zmrznjeno v tekočem dušiku.
Administration: 
Dajanje
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED DD/MM/YYYY 
DATUM ZADNJE ODOBRITVE NAVODIL ZA UPORABO
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Neoclarityn therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. 
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom Neoclarityn, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
Treatment with Neoclarityn also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables. 
Zdravljenje z zdravilom Neoclarityn je tudi bistveno zmanjšalo motnje spanja in dnevnih dejavnosti bolnika, kar so ugotavljali na podlagi meritev s štiritočkovno lestvico za oceno teh spremenljivk.
There are no known interactions of Neoclarityn with other medicines. 
Ni znanih interakcij med zdravilom Neoclarityn in drugimi zdravili.
In the case of severe renal insufficiency, Neoclarityn should be used with caution (see section 5.2). 
V primeru hude ledvične insuficience morate zdravilo Neoclarityn uporabljati previdno (glejte poglavje 5.2).
Neoclarityn effectively controlled symptoms for 24 hours. 
Zdravilo Neoclarityn učinkovito obvladuje te simptome za čas 24 ur.
As a precautionary measure, it is preferable to avoid the use of Neoclarityn during pregnancy. 
Iz previdnostnih razlogov se je med nosečnostjo uporabi zdravila Neoclarityn bolje izogibati.
The prescriber should be aware that most cases of rhinitis below 2 years of age are of infectious origin (see section 4.4) and there are no data supporting the treatment of infectious rhinitis with Neoclarityn. 
Zdravnik, ki predpiše zdravilo, naj se zaveda, da je pri otrocih, mlajših od 2 let, večina primerov rinitisa infekcijskega izvora (glejte poglavje 4.4) in da ni nobenih podatkov, ki bi govorili v prid zdravljenju infekcijskega rinitisa z zdravilom Neoclarityn.
In two placebo-controlled six week trials in patients with chronic idiopathic urticaria, Neoclarityn was effective in relieving pruritus and decreasing the size and number of hives by the end of the first dosing interval. 
V dveh s placebom kontroliranih šesttedenskih preskušanjih pri bolnikih s kronično idiopatsko urtikarijo je zdravilo Neoclarityn učinkovito blažilo srbenje in zmanjšalo velikost in število izpuščajev koprivnice že do konca prvega intervala odmerjanja.
Other medicines and Neoclarityn 
Druga zdravila in zdravilo Neoclarityn
Water had no effect on the bioavailability of Neoclarityn orodispersible tablets. 
Voda ni vplivala na biološko uporabnost zdravila Neoclarityn orodisperzibilne tablete.
Neoclarityn 2.5 mg tablets has not been evaluated in paediatric patients however in conjunction with the dose finding studies in paediatrics, the pharmacokinetics data for Neoclarityn orodispersible tablets supports the use of the 2.5 mg dose in paediatric patients 6 to 11 years of age. 
Uporabe zdravila Neoclarityn 2,5 mg tablete niso ovrednotili pri pediatričnih bolnikih, vendar pa skupaj s študijami za ugotavljanje pediatričnega odmerka tudi farmakokinetični podatki za zdravilo Neoclarityn orodisperzibilne tablete govorijo v prid uporabi 2,5 mg odmerka pri pediatričnih bolnikih starih 6 do 11 let.
However, the safety of desloratadine syrup formulation, which contains the same concentration of desloratadine as Neoclarityn oral solution, was demonstrated in three paediatric trials. 
Varnost desloratadina v obliki sirupa, ki vsebuje isto koncentracijo desloratadina kot Neoclarityn peroralna raztopina, pa so dokazali v treh preskušanjih pri pediatričnih bolnikih.
Contains lactose See leaflet for further information. 
Vsebuje laktozo Za dodatne informacije glejte navodilo za uporabo.
Therefore, the efficacy of Neoclarityn orodispersible tablet is expected to be the same as with the Neoclarityn tablet formulation. 
Zato je pričakovana učinkovitost zdravila Neoclarityn orodisperzibilne tablete enaka učinkovitosti tablet Neoclarityn.
During the marketing of Neoclarityn, cases of severe allergic reactions (difficulty in breathing, wheezing, itching, hives and swelling) have been reported very rarely. 
Med trženjem zdravila Neoclarityn so zelo redko poročali o primerih hudih alergijskih reakcij (težave z dihanjem, piskanje, srbenje, koprivnica in otekanje).
Efficacy of Neoclarityn oral solution has not been investigated in separate paediatric trials. 
Učinkovitosti zdravila Neoclarityn peroralna raztopina niso raziskovali v ločenih pediatričnih preskušanjih.
Neoclarityn orodispersible tablet contains aspartame This product contains aspartame. 
Zdravilo Neoclarityn orodisperzibilna tableta vsebuje aspartam To zdravilo vsebuje aspartam.
The efficacy of Neoclarityn tablets has not been clearly demonstrated in trials with adolescent patients 12 through 17 years of age. 
Učinkovitosti tablet Neoclarityn niso jasno dokazali v preskušanjih pri mladostnikih, starih od 12 do 17 let.
If you forget to take Neoclarityn orodispersible tablet If you forget to take your dose on time, take it as soon as possible and then go back to your regular dosing schedule. 
Če ste pozabili vzeti zdravilo Neoclarityn orodisperzibilna tableta Če ste pozabili vzeti odmerek pravočasno, ga vzemite čimprej in potem nadaljujte z ustaljenim režimom odmerjanja.
What Neoclarityn is Neoclarityn contains desloratadine which is an antihistamine. 
Kaj je zdravilo Neoclarityn Zdravilo Neoclarityn vsebuje desloratadin, ki je antihistaminik.
If you forget to take Neoclarityn 
Če ste pozabili vzeti zdravilo Neoclarityn
1 film-coated tablet 2 film-coated tablets 3 film-coated tablets 5 film-coated tablets 7 film-coated tablets 10 film-coated tablets 14 film-coated tablets 15 film-coated tablets 20 film-coated tablets 21 film-coated tablets 30 film-coated tablets 50 film-coated tablets 100 film-coated tablets 
1 filmsko obložena tableta 2 filmsko obloženi tableti 3 filmsko obložene tablete 5 filmsko obloženih tablet 7 filmsko obloženih tablet 10 filmsko obloženih tablet 14 filmsko obloženih tablet 15 filmsko obloženih tablet 20 filmsko obloženih tablet 21 filmsko obloženih tablet 30 filmsko obloženih tablet 50 filmsko obloženih tablet 100 filmsko obloženih tablet
Taking Neoclarityn is not recommended if you are pregnant or nursing a baby. 
Jemanja zdravila Neoclarityn vam ne priporočamo, če ste noseči ali če dojite.
What Neoclarityn orodispersible tablet is and what it is used for What you need to know before you take Neoclarityn orodispersible tablet How to take Neoclarityn orodispersible tablet Possible side effects 
Kaj je zdravilo Neoclarityn orodisperzibilna tableta in za kaj jo uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Neoclarityn orodisperzibilna tableta Kako jemati zdravilo Neoclarityn orodisperzibilna tableta Možni neželeni učinki
Talk to your doctor, pharmacist or nurse before taking Neoclarityn: - if you have poor kidney function. 
Pred začetkom jemanja zdravila Neoclarityn se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro: - če vam ledvice slabo delujejo.
Neoclarityn orodispersible tablet with food, drink and alcohol Neoclarityn orodispersible tablet does not need to be taken with water or liquid. 
Zdravilo Neoclarityn orodisperzibilna tableta skupaj s hrano, pijačo in alkoholom Zdravila Neoclarityn orodisperzibilna tableta vam ni treba jemati z vodo ali tekočino.
Efficacy of Neoclarityn syrup has not been investigated in paediatric trials in children less than 12 years of age. 
Učinkovitosti zdravila Neoclarityn sirup niso raziskovali v pediatričnih preskušanjih pri otrocih, mlajših od 12 let.
Neoclarityn tablets contain lactose. 
Zdravilo Neoclarityn tablete vsebuje laktozo.
In clinical studies with Neoclarityn, the following side effects were reported as: 
V kliničnih študijah z zdravilom Neoclarityn so poročali o naslednjih neželenih učinkih:
Do not use this medicine if you notice any change in the appearance of Neoclarityn orodispersible tablet. 
Ne uporabljajte tega zdravila, če opazite kakršne koli spremembe videza zdravila Neoclarityn orodisperzibilna tableta.
EU/1/00/161/001 1 tablet EU/1/00/161/002 2 tablets EU/1/00/161/003 3 tablets EU/1/00/161/004 5 tablets EU/1/00/161/005 7 tablets EU/1/00/161/006 10 tablets EU/1/00/161/007 14 tablets EU/1/00/161/008 15 tablets EU/1/00/161/009 20 tablets EU/1/00/161/010 21 tablets EU/1/00/161/011 30 tablets EU/1/00/161/012 50 tablets EU/1/00/161/013 100 tablets 
EU/1/00/161/001 1 tableta EU/1/00/161/002 2 tableti EU/1/00/161/003 3 tablete EU/1/00/161/004 5 tablet EU/1/00/161/005 7 tablet EU/1/00/161/006 10 tablet EU/1/00/161/007 14 tablet EU/1/00/161/008 15 tablet EU/1/00/161/009 20 tablet EU/1/00/161/010 21 tablet EU/1/00/161/011 30 tablet EU/1/00/161/012 50 tablet EU/1/00/161/013 100 tablet
The recommended dose of Neoclarityn is two 2.5 mg orodispersible tablets placed in the mouth once a day. 
Priporočeni odmerek zdravila Neoclarityn sta dve 2,5 mg orodisperzibilni tableti v usta enkrat na dan.
Neoclarityn oral solution, is supplied in 30, 50, 60, 100, 120, 150, 225 and 300 ml size Type III amber glass bottles closed with a plastic child resistant (C/R) screw closure having a multi-ply polyethylenefaced liner. 
Zdravilo Neoclarityn peroralna raztopina je na voljo v rjavih stekleničkah iz stekla tipa III velikosti 30, 50, 60, 100, 120, 150, 225 ali 300 ml. Stekleničke so zaprte s plastično zaporko, varno za otroke (C/R) z navojem, z večplastno oblogo s polietilenom na vrhu.
Neoclarityn has no or negligible influence on the ability to drive and use machines based on clinical trials. 
Zdravilo Neoclarityn glede na klinične študije nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Name and address of the manufacturer responsible for batch release for film coated tablets 
Ime in naslov izdelovalca, odgovornega za sproščanje serij za filmsko obložene tablete
In clinical studies in most children and adults, side effects with Neoclarityn were about the same as with a dummy solution or tablet. 
V kliničnih študijah so bili pri večini otrok in odraslih neželeni učinki pri jemanju zdravila Neoclarityn približno enaki kot pri jemanju peroralne suspenzije placeba ali tablet.
In a clinical pharmacology trial, Neoclarityn tablets taken concomitantly with alcohol did not potentiate the performance impairing effects of alcohol (see section 5.1). 
V klinični farmakološki raziskavi pri sočasnem jemanju tablet Neoclarityn in uživanju alkohola ni bilo okrepljenih škodljivih učinkov alkohola (glejte poglavje 5.1).
Additionally, Neoclarityn orodispersible tablet may be taken with or without a meal. 
Zdravilo Neoclarityn orodisperzibilna tableta se lahko jemlje s hrano ali brez nje.
In single-dose crossover studies of Neoclarityn 5 mg orodispersible tablets with Neoclarityn 5 mg conventional tablets, the formulations were bioequivalent. 
V navzkrižnih študijah primerjave enkratnega odmerka zdravila Neoclarityn 5 mg orodisperzibilne tablete z zdravilom Neoclarityn 5 mg tablete sta se ti dve formulaciji izkazali za bioekvivalentni.
Adults During the marketing of Neoclarityn, the following side effects were reported as: 
Odrasli Med trženjem zdravila Neoclarityn so poročali o naslednjih neželenih učinkih:
When Neoclarityn should be used 
Kdaj je treba uporabljati zdravilo Neoclarityn
How to store Neoclarityn orodispersible tablet Contents of the pack and other information 
Shranjevanje zdravila Neoclarityn orodisperzibilna tableta Vsebina pakiranja in dodatne informacije
Taking Neoclarityn oral solution is not recommended if you are pregnant or nursing a baby. 
Jemanja zdravila Neoclarityn peroralna raztopina vam ne priporočamo, če ste noseči ali če dojite.
What you need to know before you take Neoclarityn orodispersible tablet 
Kaj morate vedeti, preden boste vzeli zdravilo Neoclarityn orodisperzibilna tableta
Children 6 to 11 years of age: the recommended dose of Neoclarityn is one 2.5 mg orodispersible tablet placed in mouth once a day. 
Otroci, stari 6 do 11 let: Priporočeni odmerek zdravila Neoclarityn je ena 2,5 mg orodisperzibilna tableta v usta enkrat na dan.
Adverse reactions seen with Neoclarityn 
Neželeni učinki opaženi pri zdravilu Neoclarityn
During the marketing of Neoclarityn, the following side effects were reported as: 
Med trženjem zdravila Neoclarityn so poročali o naslednjih neželenih učinkih:
EU/1/00/161/059 30 ml with 1 spoon EU/1/00/161/060 50 ml with 1 spoon EU/1/00/161/061 60 ml with 1 spoon EU/1/00/161/062 100 ml with 1 spoon EU/1/00/161/063 120 ml with 1 spoon EU/1/00/161/064 150 ml with 1 spoon EU/1/00/161/067 150 ml with 1 oral syringe EU/1/00/161/065 225 ml with 1 spoon EU/1/00/161/066 300 ml with 1 spoon 
EU/1/00/161/059 30 ml z 1 odmerno žličko EU/1/00/161/060 50 ml z 1 odmerno žličko EU/1/00/161/061 60 ml z 1 odmerno žličko EU/1/00/161/062 100 ml z 1 odmerno žličko EU/1/00/161/063 120 ml z 1 odmerno žličko EU/1/00/161/064 150 ml z 1 odmerno žličko EU/1/00/161/067 150 ml z 1 odmerno brizgo za peroralno dajanje EU/1/00/161/065 225 ml z 1 odmerno žličko EU/1/00/161/066 300 ml z 1 odmerno žličko
What Neoclarityn is and what it is used for 
Kaj je zdravilo Neoclarityn in za kaj ga uporabljamo
Children 1 through 5 years of age: 2.5 ml (1.25 mg) Neoclarityn oral solution once a day. 
Otroci v starosti od 1 do 5 let: 2,5 ml (1,25 mg) peroralne raztopine Neoclarityn enkrat na dan.
Adults and adolescents (12 years of age and over) The recommended dose of Neoclarityn is one tablet once a day. 
Odrasli in mladostniki (stari 12 let ali več) Priporočeni odmerek zdravila Neoclarityn je ena tableta enkrat na dan.
As Neoclarityn oral solution contains the same concentration of desloratadine, no bioequivalence study was required and it is expected to be equivalent to the syrup and tablet. 
Ker vsebuje zdravilo Neoclarityn peroralna raztopina isto koncentracijo desloratadina, ni bila potrebna študija bioekvivalentnosti.
Use caution when taking Neoclarityn with alcohol. 
Pri sočasnem jemanju zdravila Neoclarityn in uživanju alkohola je potrebna previdnost.
At the recommended dose, Neoclarityn 5 mg orodispersible tablet was found to be bioequivalent to the Neoclarityn 5 mg conventional tablet formulation of desloratadine. 
Ugotovili so, da je zdravilo Neoclarityn orodisperzibilna tableta v priporočenem odmerku 5 mg bioekvivalentno običajni formulaciji desloratadina v obliki zdravila Neoclarityn 5 mg tablete.
Neoclarityn orodispersible tablets are supplied in unit dose blisters comprised of laminate blister film with foil lidding. 
Neoclarityn orodisperzibilne tablete so na voljo v laminatnih pretisnih omotih za enojni odmerek, ki ga sestavljata film pretisnega omota in folija ki ga prekriva.
Neoclarityn 5 mg film-coated tablets are packed in blisters in packs of 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50 or 100 tablets. 
5 mg filmsko obložene tablete Neoclarityn so na voljo v pretisnih omotih po 1, 2, 3, 5, 7, 10, 14, 15, 20, 21, 30, 50 ali 100 tablet.
Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Neoclarityn orodispersible tablets. 
Kar zadeva trajanje zdravljenja, bo vaš zdravnik najprej ugotovil vrsto alergijskega rinitisa, ki jo imate, in na podlagi tega določil, kako dolgo naj bi jemali zdravilo Neoclarityn orodisperzibilna tableta.
Neoclarityn with food, drink and alcohol Neoclarityn may be taken with or without a meal. 
Zdravilo Neoclarityn skupaj s hrano, pijačo in alkoholom Zdravilo Neoclarityn se lahko jemlje s hrano ali brez nje.
If you take more Neoclarityn orodispersible tablet than you should Take Neoclarityn orodispersible tablet only as prescribed for you. 
Če ste vzeli večji odmerek zdravila Neoclarityn orodisperzibilna tableta, kot bi smeli Zdravilo Neoclarityn orodisperzibilno tableto jemljite le tako, kot vam je bilo predpisano.
What Neoclarityn orodispersible tablet is and what it is used for 
Kaj je zdravilo Neoclarityn orodisperzibilna tableta in za kaj ga uporabljamo
Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Neoclarityn. 
Kar zadeva trajanje zdravljenja, bo vaš zdravnik najprej ugotovil vrsto alergijskega rinitisa, ki jo imate, in na podlagi tega določil, kako dolgo naj bi jemali zdravilo Neoclarityn.